AnaptysBio, Inc. (NASDAQ:ANAB) – Research analysts at Wedbush increased their FY2017 EPS estimates for shares of AnaptysBio in a report issued on Thursday. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings per share of ($1.59) for the year, up from their prior estimate of ($1.76). Wedbush currently has a “Positive” rating and a $82.00 target price on the stock. Wedbush also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.35) EPS, Q1 2018 earnings at ($0.41) EPS, Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.50) EPS, Q4 2018 earnings at ($0.54) EPS, FY2018 earnings at ($1.90) EPS, FY2019 earnings at ($2.19) EPS, FY2020 earnings at ($2.06) EPS and FY2021 earnings at ($0.69) EPS.
A number of other research firms also recently weighed in on ANAB. Royal Bank Of Canada increased their target price on AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Credit Suisse Group increased their target price on AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Robert W. Baird set a $69.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research downgraded AnaptysBio from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $76.00 target price (up previously from $35.00) on shares of AnaptysBio in a report on Friday, October 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. AnaptysBio has a consensus rating of “Buy” and an average price target of $81.00.
COPYRIGHT VIOLATION WARNING: This report was originally published by Stock Observer and is the property of of Stock Observer. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.thestockobserver.com/2017/11/15/wedbush-equities-analysts-boost-earnings-estimates-for-anaptysbio-inc-anab.html.
AnaptysBio (ANAB) opened at $71.08 on Monday. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $74.00. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09.
AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02.
In other news, major shareholder Holdings A/S Novo sold 356,300 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now owns 1,936,604 shares of the company’s stock, valued at $40,862,344.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC raised its stake in shares of AnaptysBio by 3.2% in the third quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock worth $34,330,000 after buying an additional 30,000 shares during the period. Citadel Advisors LLC bought a new position in shares of AnaptysBio in the third quarter worth about $20,406,000. Artal Group S.A. raised its stake in shares of AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the period. Vanguard Group Inc. raised its stake in shares of AnaptysBio by 22.6% in the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after buying an additional 37,932 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of AnaptysBio by 210.2% in the third quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock worth $6,363,000 after buying an additional 124,219 shares during the period. 59.04% of the stock is currently owned by hedge funds and other institutional investors.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.